JP2018505144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505144A5 JP2018505144A5 JP2017532799A JP2017532799A JP2018505144A5 JP 2018505144 A5 JP2018505144 A5 JP 2018505144A5 JP 2017532799 A JP2017532799 A JP 2017532799A JP 2017532799 A JP2017532799 A JP 2017532799A JP 2018505144 A5 JP2018505144 A5 JP 2018505144A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- cxcl12
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1422502.3 | 2014-12-17 | ||
| GB201422502 | 2014-12-17 | ||
| PCT/EP2015/079384 WO2016096640A2 (en) | 2014-12-17 | 2015-12-11 | Anti-cxcl12 antibody molecules and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018505144A JP2018505144A (ja) | 2018-02-22 |
| JP2018505144A5 true JP2018505144A5 (cg-RX-API-DMAC10.html) | 2019-01-31 |
Family
ID=54848570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532799A Ceased JP2018505144A (ja) | 2014-12-17 | 2015-12-11 | 抗ｃｘｃｌ１２抗体分子およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10647766B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3233112A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2018505144A (cg-RX-API-DMAC10.html) |
| CN (1) | CN107207590A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2015366512A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2970857A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL252932A0 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016096640A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4435003A4 (en) * | 2021-12-27 | 2025-10-29 | Epi Biotech Co Ltd | ANTIBODY AGAINST CXCL 12 AND COMPOSITION INCLUDING IT FOR THE TREATMENT OF HAIR LOSS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329178B2 (en) * | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| JP5380287B2 (ja) * | 2006-07-18 | 2014-01-08 | ノクソン・ファルマ・アクチエンゲゼルシャフト | Ｓｄｆ−１結合核酸 |
| JP5244785B2 (ja) * | 2006-08-11 | 2013-07-24 | 小野薬品工業株式会社 | ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体 |
| WO2008021263A2 (en) * | 2006-08-11 | 2008-02-21 | Medarex, Inc. | Methods of indentifying antibodies that bind oligomeric forms of chemokines and uses thereof |
| AU2007337983A1 (en) * | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies |
| GB201002238D0 (en) * | 2010-02-10 | 2010-03-31 | Affitech As | Antibodies |
| MX361929B (es) * | 2010-11-19 | 2018-12-19 | Eisai R&D Man Co Ltd Star | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. |
-
2015
- 2015-12-11 EP EP15808213.1A patent/EP3233112A2/en not_active Withdrawn
- 2015-12-11 JP JP2017532799A patent/JP2018505144A/ja not_active Ceased
- 2015-12-11 CN CN201580073656.9A patent/CN107207590A/zh active Pending
- 2015-12-11 US US15/535,976 patent/US10647766B2/en not_active Expired - Fee Related
- 2015-12-11 CA CA2970857A patent/CA2970857A1/en not_active Abandoned
- 2015-12-11 AU AU2015366512A patent/AU2015366512A1/en not_active Abandoned
- 2015-12-11 WO PCT/EP2015/079384 patent/WO2016096640A2/en not_active Ceased
-
2017
- 2017-06-15 IL IL252932A patent/IL252932A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7798932B2 (ja) | 癌の治療のためのクローディン１８．２に対する抗体を含む治療法 | |
| CN108136025B (zh) | 一种使用免疫调节治疗癌症的新颖方法 | |
| TWI457346B (zh) | 包含專一性辨識ｃｄ３８之抗體及環磷醯胺（ｃｙｃｌｏｐｈｏｓｐｈａｍｉｄｅ）之抗腫瘤組合 | |
| TWI457124B (zh) | 包含專一性辨識ｃｄ３８之抗體及長春新鹼（ｖｉｎｃｒｉｓｔｉｎｅ）之抗腫瘤組合 | |
| CN103347898B (zh) | 包括与肿瘤相关抗原结合抗体的联合治疗 | |
| KR102757960B1 (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| US20120117670A1 (en) | Humanized axl antibodies | |
| IL263466B1 (en) | Anti-cd3 antibodies and methods of using them | |
| JP2015509947A5 (cg-RX-API-DMAC10.html) | ||
| TW201307392A (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| JP2022536602A (ja) | 濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法 | |
| KR20180088445A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| JP2020507339A (ja) | 抗ｇ−ｃｓｆ抗体及びその使用 | |
| JP2022553851A5 (cg-RX-API-DMAC10.html) | ||
| CN116744976A (zh) | 用于治疗实体癌的her3放射免疫疗法 | |
| JP2024054123A (ja) | 癌の治療のための配合剤 | |
| KR20230005903A (ko) | 항-CD79b 면역접합체를 사용하는 방법 | |
| JP2023519807A5 (cg-RX-API-DMAC10.html) | ||
| AU2021378793B2 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer | |
| JP2024519907A (ja) | 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用 | |
| CN111094353A (zh) | 用于癌症的组合治疗 | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JP2022513036A (ja) | がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ | |
| JP2024502670A5 (cg-RX-API-DMAC10.html) | ||
| JP2018505144A (ja) | 抗ｃｘｃｌ１２抗体分子およびその使用 |